|
Quotes & Info
|
| SCLN > SEC Filings for SCLN > Form 8-K on 11-Sep-2012 | All Recent SEC Filings |
11-Sep-2012
Change in Directors or Principal Officers, Financial Statements and
(b) On September 10, 2012, SciClone Pharmaceuticals, Inc. (the "Company") announced that Mark Lotter will resign at the end of 2012 from his position as a director of the Company and as Chief Executive Officer of China Operations.
The press release announcing Mr. Lotter's resignation is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.
(d) The following exhibits are included with this Current Report on Form 8-K:
|
|